A background note can be accessed here: NITI Aayog’s Roadmap for Ayurveda in Globally Recognised Healthcare System
The NITI Aayog roadmap argues that Ayurveda's international expansion will depend less on cultural promotion and more on building scientific credibility through clinical evidence, pharmacovigilance, quality assurance, and regulatory alignment. To what extent does this represent a fundamental shift in India's strategy for globalising Ayurveda?
The roadmap marks an important evolution in India's strategy for globalising Ayurveda by placing greater emphasis on scientific credibility, quality assurance, pharmacovigilance, and regulatory alignment. However, it understates the methodological challenges involved in generating internationally accepted clinical evidence for a whole-system medicine. Ayurveda’s clinical logic is intrinsically individualised and multimodal, whereas dominant global evidence standards favour standardised, single-intervention randomised controlled trials (RCTs). Applying conventional RCT frameworks without methodological adaptation risks reducing Ayurveda to isolated compounds for regulatory approval, while discarding the system's holistic premise.
A more sustainable pathway is methodological innovation. India must transition from volume-driven, advocacy-grade research to rigorous whole-system designs, pragmatic trials, and real-world evidence. A critical, underutilised enabler is Ayurveda’s inclusion in the WHO’s ICD-11 Traditional Medicine Module, which standardises clinical documentation. Scientific legitimacy also requires the transparent publication of null or negative findings and robust, independent pharmacovigilance. International credibility will depend on methodologically sound inquiry that clarifies exactly what works, for whom, under what conditions, and at what risk.
The roadmap proposes reforms spanning practitioner mobility, Medical Value Travel, insurance acceptance, WHO-GMP manufacturing, and international regulatory harmonisation. Which of these reforms is likely to be the most critical for integrating Ayurveda into mainstream healthcare systems abroad rather than expanding it as a wellness market?
Expanding the international wellness market and integrating Ayurveda into mainstream healthcare systems involve different policy and regulatory requirements. While Medical Value Travel and WHO-GMP manufacturing broaden international access and strengthen product quality, they do not by themselves establish routine clinical use within health systems. The most consequential reform is regulatory recognition supported by reimbursement frameworks, because these determine whether Ayurvedic interventions become part of standard care.
Achieving this requires indication-level evidence linked to clearly defined clinical use cases rather than broad claims about Ayurveda as a whole. A pragmatic sequencing strategy should prioritise a limited set of tracer conditions, such as musculoskeletal pain or functional gastrointestinal disorders, for which guideline-grade evidence can be generated. Cross-border clinical partnerships are essential to co-design referral protocols, shared-care models, and escalation pathways with host-country physicians. Reimbursement pilots for these well-defined indications can then generate the comparative cost-effectiveness evidence that insurers and health systems require. Over time, mainstream integration will emerge through the cumulative acceptance of individual indications supported by robust evidence, aligned regulation, and demonstrable clinical value.
The report proposes a phased roadmap to 2047 with coordinated responsibilities across government, regulators, academia, healthcare providers, and industry. What governance arrangements will be necessary to translate this long-term vision into measurable outcomes?
Translating a vision extending to 2047 into measurable public health outcomes requires a governance structure that clearly separates promotional functions from evidence assessment and evaluation. A Mission Steering Group can provide the necessary inter-ministerial coordination, while an independent health technology assessment (HTA)-style body should oversee evidence curation, safety surveillance, and quality assurance to strengthen international confidence.
Governance should also measure progress through outcomes that reflect meaningful health system integration rather than activity alone. Relevant indicators include the inclusion of Ayurvedic interventions in foreign clinical guidelines, insurance reimbursement decisions, adoption within regulated care pathways, and stronger pharmacovigilance reporting, which signals a maturing regulatory ecosystem.
Finally, governance must carefully sequence commercial expansion with scientific validation. Scaling internationally before evidence generation and quality systems are sufficiently mature risks creating a lasting trust deficit. A learning governance architecture, supported by an independent scientific advisory board comprising public health experts, methodologists, and international partners, can continuously review evidence, guide implementation, and ensure that long-term commercial growth rests on a durable foundation of clinical integrity.